Bioclinica Acquires Saliency


Bioclinica has announced that it has acquired Silicon Valley-based Saliency. Bioclinica will integrate the company's AI technology into its Imaging.

The Saliency platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images. These newly created models can then be used to screen, redact, or interpret medical images to support a wide range of therapeutic areas.

Saliency's co-founders, Kevin Thomas, MD/PhD, candidate at Stanford University School of Medicine and Łukasz Kidziński, PhD, formerly of Stanford's Bioengineering & Statistics, will join Bioclinica's Image Science team.

For more information, click here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.